Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toripalimab (Primary) ; YH 003 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Leiomyosarcoma; Liver metastases; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours; Tongue cancer; Uterine leiomyoma; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Eucure Biopharma

Most Recent Events

  • 24 Oct 2023 Results of part 1 (n=20) presented at the 48th European Society for Medical Oncology Congress.
  • 17 Oct 2023 According to an Eucure Biopharma media release, the company will present data from this study at the ESMO Congress 2023.
  • 09 Dec 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top